Haleon plc (HLN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Weybridge, United Kingdom. Der aktuelle CEO ist Brian James McNamara.
HLN hat IPO-Datum 2022-07-25, 24,561 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $43.23B.
Haleon plc is a consumer healthcare company headquartered in Brentford, United Kingdom, engaged in the research, development, manufacture, and distribution of over-the-counter health and wellness products across North America, Europe, the Middle East, Africa, Latin America, and Asia Pacific. The company's extensive portfolio spans therapeutic oral health, pain relief, respiratory health, digestive health, vitamins, minerals, and supplements, featuring globally recognized brands including Panadol, Voltaren, Advil, Sensodyne, Theraflu, Otrivin, Polident, parodontax, and Centrum. Since its incorporation in 2021 and rebranding to Haleon plc in February 2022, the company has positioned itself as a leading player in the consumer healthcare sector.
